Medicago, a Canadian subsidiary of Mitsubishi Tanabe Pharma, said on March 12 that it has successfully produced a viable vaccine candidate for COVID-19 just 20 days after obtaining the gene of the novel coronavirus causing the disease. Medicago said that…
To read the full story
Related Article
- Medicago Inks COVID-19 Vaccine Deal with Canadian Govt
October 27, 2020
- Medicago Begins PI Trial of COVID-19 Vaccine in Canada
July 16, 2020
- Medicago, GSK Team Up to Develop Adjuvanted COVID-19 Vaccine, PI to Commence in Mid-July
July 9, 2020
- Medicago’s COVID-19 Vaccine Shows Positive Animal Data, Clinical Trial Expected to Wrap Up by November 2021
May 19, 2020
- Govt Officials Urge Japan Pharma Companies to Be More Proactive in Coronavirus Vaccine Development
May 12, 2020
BUSINESS
- Sanofi Bets on Immunotherapy to Delay Onset of Type 1 Diabetes
December 19, 2025
- Japan’s 1st Eylea Biosimilar to Reach Market on January 7
December 19, 2025
- Padcev-Keytruda Pair Makes Mark in Cisplatin-Eligible MIBC: Astellas
December 19, 2025
- Daiichi Sets February Launch for Japan’s 1st OTC Morning-After Pill
December 19, 2025
- Takeda’s TYK2 Inhibitor Scores PIII Win in Psoriasis Trials, Tops Otezla on Key Metrics
December 19, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





